<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.5-a.1'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//nxtin.health/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://nxtin.health/2026/11/12/neobe-raises-6-8m-to-break-down-the-barriers-that-stop-cancer-treatments-from-working/</loc>
  <lastmod>2026-11-12T19:56:54Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Neobe raises $6.8M to break down the barriers that stop cancer treatments from working</news:title>
   <news:publication_date>2026-11-12T19:41:21Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/efferon-raises-e4-3-million-to-expand-its-sepsis-treatment-technology-into-new-markets/</loc>
  <lastmod>2026-11-12T19:26:10Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Efferon raises €4.3 million to expand its sepsis treatment technology into new markets</news:title>
   <news:publication_date>2026-11-12T19:26:08Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/kardi-ai-finds-its-rhythm-with-record-e5-3m-series-a/</loc>
  <lastmod>2026-11-12T18:53:33Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Kardi AI finds its rhythm with record €5.3m Series A</news:title>
   <news:publication_date>2026-11-12T18:53:30Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/curia-expands-fermentation-capacity-in-leon/</loc>
  <lastmod>2026-11-12T20:12:35Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Curia expands fermentation capacity in León</news:title>
   <news:publication_date>2026-11-12T18:07:00Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/fighting-cancer-meps-call-for-stronger-preventive-measures/</loc>
  <lastmod>2026-11-12T13:20:13Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Fighting cancer: MEPs call for stronger preventive measures</news:title>
   <news:publication_date>2026-11-12T13:20:11Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/bringing-better-treatments-to-patients-faster-norrsken-vc-investment-why-weve-invested-in-orakl/</loc>
  <lastmod>2026-11-12T13:09:06Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Bringing better treatments to patients faster. Norrsken VC Investment: Why we’ve invested in Orakl</news:title>
   <news:publication_date>2026-11-12T13:09:04Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/civil-protection-mechanism-making-the-eu-crisis-ready-improved-cross-border-cooperation-in-response-to-health-emergencies/</loc>
  <lastmod>2026-11-12T12:49:43Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Civil protection mechanism - making the EU crisis-ready; improved cross-border cooperation in response to health emergencies</news:title>
   <news:publication_date>2026-11-12T12:49:41Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/oh-thats-why-estonia-accelerates-so-fast-brilliant-work-behind-the-genius-slogan-our-job-is-making-illegal-things-legal/</loc>
  <lastmod>2026-11-12T12:10:23Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Oh, that&amp;#039;s why Estonia accelerates so fast! Brilliant work behind the genius slogan: “Our job is making illegal things legal.”</news:title>
   <news:publication_date>2026-11-12T12:04:59Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/ai-in-democracy-ensuring-oversight-and-compliance-with-eu-values/</loc>
  <lastmod>2026-11-12T12:25:58Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>AI in democracy: ensuring oversight and compliance with EU values</news:title>
   <news:publication_date>2026-11-12T11:01:00Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/12/biomatter-raises-18m-series-a-to-scale-its-ai-powered-enzyme-design-for-global-industry-leaders/</loc>
  <lastmod>2026-11-12T06:51:49Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Biomatter raises $18M series A to scale its AI-powered enzyme design for global industry leaders</news:title>
   <news:publication_date>2026-11-12T06:48:29Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/11/coloplast-opens-new-factory-in-portugal-to-support-global-growth/</loc>
  <lastmod>2026-11-11T14:59:23Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Coloplast opens new factory in Portugal to support global growth</news:title>
   <news:publication_date>2026-11-11T14:59:20Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/11/cyprus-approves-national-blood-strategy-to-modernise-blood-services/</loc>
  <lastmod>2026-11-11T14:49:50Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Cyprus approves National Blood Strategy to modernise blood services</news:title>
   <news:publication_date>2026-11-11T14:49:48Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/11/switchpoint-bio-raises-5-3m-pre-seed-to-make-treatment-response-visible-from-blood/</loc>
  <lastmod>2026-11-11T14:27:01Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Switchpoint Bio raises $5.3M pre-seed to make treatment response visible from blood</news:title>
   <news:publication_date>2026-11-11T14:26:59Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/11/paolo-will-hear-his-childrens-voices-again-a-pioneering-robotic-procedure-at-policlinico-di-milano/</loc>
  <lastmod>2026-11-11T10:04:35Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Paolo will hear his children&amp;#039;s voices again - a pioneering robotic procedure at Policlinico di Milano</news:title>
   <news:publication_date>2026-11-11T10:04:34Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/11/giving-the-voice-a-face-semmelweis-researchers-use-virtual-avatars-to-help-patients-with-schizophrenia/</loc>
  <lastmod>2026-11-11T09:53:32Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Giving the voice a face: Semmelweis researchers use virtual avatars to help patients with schizophrenia</news:title>
   <news:publication_date>2026-11-11T09:01:40Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/11/2026-access-to-medicine-index/</loc>
  <lastmod>2026-11-11T08:49:34Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>2026 Access to Medicine index</news:title>
   <news:publication_date>2026-11-11T08:49:32Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://nxtin.health/2026/11/11/portugal-involved-in-one-third-of-clinical-trials-selected-for-europes-fast-eu-initiative/</loc>
  <lastmod>2026-11-12T06:30:00Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>NXTin health</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Portugal involved in one-third of clinical trials selected for Europe&amp;#039;s FAST-EU initiative</news:title>
   <news:publication_date>2026-11-11T03:06:00Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
